All Oncology News

Obesity is more prevalent in cancer survivors, specifically in those with a history of breast or colorectal cancer, compared with those without any history of disease.

A move by CVS Health to place in-house physician dispensaries out-of-network for purposes of Medicare Part D drug payment would force hundreds of thousands of cancer patients across the country to find alternate sources for their oral oncolytic drugs.

Yvonee Saenger, MD, discusses ongoing developments with immunotherapy in melanoma.

Emily M. Ko, MD, discusses the implications of two clinical trial findings for patients with endometrial cancer, and how several risk factors may lead to a surgical treatment delay.

The FDA has granted an accelerated approval to blinatumomab (Blincyto) for the treatment of pediatric and adolescent patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

The FDA has assigned a standard review designation to a new drug application for binimetinib as a treatment for patients with NRAS-mutant advanced melanoma.

The European Commission has approved crizotinib (Xalkori) as a treatment for patients with advanced ROS1-positive non–small cell lung cancer.

Atezolizumab (Tecentriq) improved survival compared with docetaxel in patients with advanced non–small cell lung cancer following the failure of platinum-based chemotherapy.

Maria-Victoria Mateos, MD, PhD, provides insight on a subanalysis of the TOURMALINE-MM1 trial, the impact of ixazomib's (Ninlaro's) approval, and the future of triplet combinations in the treatment multiple myeloma.

Bruce Cheson, MD, discusses how frontline treatment for chronic lymphocytic leukemia has evolved well beyond a "one-size-fits-all" approach, with patient and disease characteristics and physician/patient discussions determining the optimal therapeutic approach.

The FDA has approved ofatumumab in combination with fludarabine and cyclophosphamide as a treatment for patients with relapsed chronic lymphocytic leukemia.

Richard J. Bold, MD, discusses the reasoning to break gastroesophageal junction cancers into multiple subgroups and why it is important for treatment and surgical decisions.

A new drug application has been submitted for brigatinib (AP26113) as a potential treatment for patients with advanced ALK-positive non–small cell lung cancer following resistance or intolerance to crizotinib (Xalkori).

Treatment with pacritinib significantly reduced spleen volume but failed to improve total symptom score compared with best available therapy for thrombocytopenic patients with high-risk myelofibrosis.

John L. Marshall, MD, discusses second-line treatment options for patients with metastatic colorectal cancer, along with who is most appropriate to receive regorafenib (Stivarga) and how to manage doses and toxicities when using the multikinase inhibitor.

Zev Wainberg, MD, discusses a plethora of immunotherapy agents, such as pembrolizumab (Keytruda), durvalumab, avelumab, and apatinib, for the treatment of patients with gastric cancer, as well as a number of ongoing clinical trials in this space.

Jennifer Woyach, MD, discussed using the FDA-approved agents ibrutinib (Imbruvica), idelalisib (Zydelig), and venetoclax (Venclexta) in a hypothetical patient scenario, and highlighted emerging targets and treatments in relapsed/refractory chronic lymphocytic leukemia.

Colorectal cancer mortality rates have been on the decline in California for both men and women since the mid-1990s, but for one group—Hispanic men—rates have remained essentially unchanged, and a new study suggests that lower rates of screening may be the chief driver of this disparity.

The multikinase inhibitor midostaurin (PKC412) demonstrated an overall response rate of 60% in patients with advanced systemic mastocytosis.

Daratumumab (Darzalex) significantly improved progression-free survival when added to bortezomib (Velcade) and dexamethasone for patients with relapsed or refractory multiple myeloma.

Approximately 46% of patients with breast cancer at high risk for recurrence but low genomic risk with the 70-gene breast cancer recurrence assay (MammaPrint) might not require adjuvant chemotherapy.

David Reardon, MD, discusses the potential for immunotherapy in brain cancer, its immunogenicity, and what preliminary data have shown so far regarding checkpoint inhibition.

Richard Levine, MD, discusses the selection of therapies available for patients with metastatic castration-resistant prostate cancer and the next steps in the field.

Kosj Yamoah, MD, discusses health disparities in prostate cancer and unanswered questions researchers still need to tackle.

Jedd D. Wolchok, MD, PhD, discusses two pivotal studies, their impacts, and how far the field of immunotherapy has come in melanoma.

Julio Pow-Sang, MD, discusses the significance of assessing risk status, options for patients with prostate cancer whose risk status falls in a "grey-zone," and how technology is helping oncologists more accurately characterize risk.

Jingsong Zhang, MD, PhD, discusses his vision for treating patients with metastatic castration-resistant prostate cancer.

Michael Poch, MD, provides deeper insight into how immunotherapy has propelled the field of bladder cancer forward, as well as the research that still needs to be done.

Mayer Fishman, MD, discusses the therapeutic landscape in renal cell carcinoma and the next steps needed to further advance the field.

The FDA has granted a priority review to a new drug application for rucaparib as a treatment for patients with BRCA-positive advanced ovarian cancer who have received at least 2 prior lines of chemotherapy.